Ataxin-2
Official Title
A Phase 1 Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB105 Administered Intrathecally to Adults With Amyotrophic Lateral Sclerosis With or Without Poly-CAG Expansion in the Ataxin-2 Gene
Study Details
The purpose of the study is to examine the safety and tolerability of a study drug in participants with sporadic ALS (amyotrophic lateral sclerosis).
Principal Investigator
Dr. Robert Bucelli
IRB Number
202007038
Eligibility
1. Participants must be 18 or older
2. Participants must have ALS
3. Participants must have a caregiver available for the duration of the research study
Volunteer Information
For more information about this study, contact Volunteer for Health at:
- 314.362.1000
- rprstaff@wustl.edu